Overview

* Vanda Q2 revenue rises 4% yr/yr to $52.6 mln, no analyst estimate provided

* Net loss widens to $27.2 mln in Q2 from $4.5 mln in Q2 2024

* Fanapt revenue grows 27% yr/yr, driven by sales efforts and brand campaign

Outlook

* Vanda expects 2025 revenue between $210 mln and $250 mln

* Company forecasts year-end 2025 cash between $280 mln and $320 mln

* Vanda anticipates continued Fanapt revenue growth in coming quarters

* Company expects significant regulatory milestones in coming months

Result Drivers

* FANAPT SALES GROWTH - Driven by expanded sales efforts and direct-to-consumer brand awareness campaign

* REGULATORY MILESTONES - Significant upcoming milestones expected to strengthen commercial portfolio

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $52.59

Revenue bln

Q2 -$0.46

Adjusted

EPS

Q2 EPS -$0.46

Q2 Net -$27.21

Income mln

Q2 Basic -$0.46

EPS

Q2 $91.09

Operatin mln

g

Expenses

Q2 -$38.50

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc ( VNDA ) is $13.00, about 64.1% above its July 30 closing price of $4.67

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)